These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 30168492)

  • 1. Therapeutic implications of nano-encapsulated rifabutin, azithromycin & ethambutol against experimental
    Grewal TK; Majeed S; Sharma S
    Indian J Med Res; 2018 Jun; 147(6):594-602. PubMed ID: 30168492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group.
    Havlir DV; Dubé MP; Sattler FR; Forthal DN; Kemper CA; Dunne MW; Parenti DM; Lavelle JP; White AC; Witt MD; Bozzette SA; McCutchan JA
    N Engl J Med; 1996 Aug; 335(6):392-8. PubMed ID: 8676932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of moxifloxacin by itself and in combination with ethambutol, rifabutin, and azithromycin in vitro and in vivo against Mycobacterium avium.
    Bermudez LE; Inderlied CB; Kolonoski P; Petrofsky M; Aralar P; Wu M; Young LS
    Antimicrob Agents Chemother; 2001 Jan; 45(1):217-22. PubMed ID: 11120969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multifocal M. intracellulare osteomyelitis in an immunocompetent child.
    Raszka WV; Trinh TT; Zawadsky PM
    Clin Pediatr (Phila); 1994 Oct; 33(10):611-6. PubMed ID: 7813141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolerability Outcomes of American Thoracic Society/Infectious Diseases Society of America Guideline-Recommended Multidrug Antibiotic Treatment for Mycobacterium avium Complex Pulmonary Disease in US Medicare Beneficiaries With Bronchiectasis.
    Ku JH; Henkle E; Carlson KF; Marino M; Brode SK; Marras TK; Winthrop KL
    Chest; 2024 May; 165(5):1058-1069. PubMed ID: 38086472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic drug monitoring in the treatment of Mycobacterium avium complex lung disease.
    Koh WJ; Jeong BH; Jeon K; Lee SY; Shin SJ
    Am J Respir Crit Care Med; 2012 Oct; 186(8):797-802. PubMed ID: 22878282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initial (6-month) results of three-times-weekly azithromycin in treatment regimens for Mycobacterium avium complex lung disease in human immunodeficiency virus-negative patients.
    Griffith DE; Brown BA; Murphy DT; Girard WM; Couch L; Wallace RJ
    J Infect Dis; 1998 Jul; 178(1):121-6. PubMed ID: 9652431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of rifabutin-loaded microspheres for treatment of Mycobacterium avium-infected macrophages and mice.
    Barrow EL; Barrow WW; Quenelle DC; Westbrook L; Winchester GA; Staas JK
    Drug Deliv; 2007 Mar; 14(3):119-27. PubMed ID: 17454031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Azithromycin-containing regimens for treatment of Mycobacterium avium complex lung disease.
    Griffith DE; Brown BA; Girard WM; Griffith BE; Couch LA; Wallace RJ
    Clin Infect Dis; 2001 Jun; 32(11):1547-53. PubMed ID: 11340525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent development in the treatment and prevention of disseminated Mycobacterium avium complex (MAC).
    Schouten JT; Whittemore S
    STEP Perspect; 1996; 8(3):5-6. PubMed ID: 11364267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study Group.
    Shafran SD; Singer J; Zarowny DP; Phillips P; Salit I; Walmsley SL; Fong IW; Gill MJ; Rachlis AR; Lalonde RG; Fanning MM; Tsoukas CM
    N Engl J Med; 1996 Aug; 335(6):377-83. PubMed ID: 8676931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determinants of rifabutin-associated uveitis in patients treated with rifabutin, clarithromycin, and ethambutol for Mycobacterium avium complex bacteremia: a multivariate analysis. Canadian HIV Trials Network Protocol 010 Study Group.
    Shafran SD; Singer J; Zarowny DP; Deschênes J; Phillips P; Turgeon F; Aoki FY; Toma E; Miller M; Duperval R; Lemieux C; Schlech WF
    J Infect Dis; 1998 Jan; 177(1):252-5. PubMed ID: 9419201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early results (at 6 months) with intermittent clarithromycin-including regimens for lung disease due to Mycobacterium avium complex.
    Griffith DE; Brown BA; Cegielski P; Murphy DT; Wallace RJ
    Clin Infect Dis; 2000 Feb; 30(2):288-92. PubMed ID: 10671330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of oral antimycobacterials and dosing guidance for Mycobacterium avium complex treatment in cystic fibrosis.
    Martiniano SL; Wagner BD; Brennan L; Wempe MF; Anderson PL; Daley CL; Anthony M; Nick JA; Sagel SD
    J Cyst Fibros; 2021 Sep; 20(5):772-778. PubMed ID: 34030986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of rifabutin alone and in combination with clofazimine, kanamycin and ethambutol against Mycobacterium intracellulare infections in mice.
    Saito H; Sato K
    Tubercle; 1989 Sep; 70(3):201-5. PubMed ID: 2559522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of azithromycin and rifabutin in preventing infection by Mycobacterium avium complex in beige mice.
    Bermudez LE; Petrofsky M; Inderlied CB; Young LS
    J Antimicrob Chemother; 1995 Oct; 36(4):641-6. PubMed ID: 8591938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progress report: prophylaxis and therapy for MAC.
    Currier J
    AIDS Clin Care; 1996 Jun; 8(6):45-8. PubMed ID: 11363599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MAC management.
    PI Perspect; 1996 Nov; (No 20):16-7. PubMed ID: 11363967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention strategies for Mycobacterium avium-intracellulare complex (MAC) infection. A review of recent studies in patients with AIDS.
    Cohn DL
    Drugs; 1997; 54 Suppl 2():8-15; discussion 28-9. PubMed ID: 9358195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk-benefit assessment of therapies for Mycobacterium avium complex infections.
    Griffith DE
    Drug Saf; 1999 Aug; 21(2):137-52. PubMed ID: 10456381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.